The influence of 3α,7α-dihydroxy-12-keto-5β-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 3, 2008, Pages 137-142

  Mikov, Momir ^a   Al Salami, Hani ^a   Golocorbin Kon, Svetlana ^b   Skrbic, Ranko ^c   Raskovic, Aleksandar ^b   Fawcett, J Paul ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c Medical Faculty   (Bosnia and Herzegovina)

Author keywords

7 dihydroxy 12 keto 5 cholanate; Bile acid; Diabetes; Gliclazide; Glucose; Pharmacokinetics; Rat; Sodium 3

Indexed keywords

3ALPHA,7ALPHA DIHYDROXY 12 KETO 5BETA CHOLANATE; ANTIDIABETIC AGENT; GLICLAZIDE; GLUCOSE; UNCLASSIFIED DRUG; 3ALPHA,7ALPHA DIHYDROXY 12 OXO 5BETA CHOLANATE; 3ALPHA,7ALPHA-DIHYDROXY-12-OXO-5BETA-CHOLANATE; CHENODEOXYCHOLIC ACID; DRUG DERIVATIVE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOGLYCEMIC ACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR RAT; ANIMAL; BIOAVAILABILITY; BLOOD; DRUG COMBINATION; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CHENODEOXYCHOLIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLICLAZIDE; HYPOGLYCEMIC AGENTS; MALE; MASS SPECTROMETRY; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 56249104781     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191110     Document Type: Article

References (35)

1. Butler A.E., Janson J., Bonner-Weir S., Ritzel R, Rizza R.A., Butler P.C. (2003): Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 52, 102-110.
2. Rendell M. (2004): The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 64, 1339-1358.
3. Yaris F., Yaris B., Kadioglu M., Ulku C., Kesim M., Kalyoncu N.I. (2004): Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol., 18, 619-621.
4. Garcia-Bournissen, F., Feig D.S., Koren G. (2003): Maternal-fetal transport of hypoglycaemic drugs. Clin. Pharmacokinet., 42, 303-313.
5. Campbell D.B., Lavielle R., Nathan C. (1991): The mode of action and clinical pharmacology of gliclazide: a review: Diabetes Res. Clin. Pract., 14 (Suppl 2), 521-536.
6. Smith R.J. (1990): Effects of the sulfonylureas on muscle glucose homeostasis. Am. J. Med., 89, 38S-43S; discussion 51S-53S.
7. Mamputu J.C., Renier G. (2001): Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein. Metabolism, 50, 688-695.
8. Renier G., Desfaits A.C., Serri O. (2000): Effect of gliclazide on monocyte endothelium interactions in diabetes. J. Diabetes Complica., 14, 215-223.
9. Palmer K.J., Brogden R.N. (1993): Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs, 46, 92-125.
10. Tsiani E., Ramlal T., Leiter L.T., Klip A., Fantus I. (1995): Stimulation of glucose uptake and increased plasma membrane content of glucose transport in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology, 136, 2505-2512.
11. Merlob P., Levitt O., Stahl B (2002): Oral antihyperglycemic agents during pregnancy and lactation: a review. Paediatr. Drugs, 4: 755-760.
12. Rieutord A., Stupans I., Shenfield G.M., Gross A.S. (1995): Gliclazide hydroxylation by rat liver microsomes. Xenobiotica, 25: 1345-1354.
13. Mesiha M.S., Ponnapula S., Plakogiannis F. (2002): Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha-tocopherol dispersions. Int. J. Pharm., 249, 1-5.
14. Mrestani Y., Marestani Z., Neubert R.H. (2001): The effect of a functional group in penicillin derivatives on the interaction with bile salt micelles studied by micellar electrokinetic chromatography. Electrophoresis, 22, 3573-3577.
15. Mikov M., Kevresan S., Kuhajda K., Jakovljevic V., Vasovic V. (2004): 3-alpha,7-alpha-dihydroxy-12-oxo-5-beta-cholanate as blood - brain barrier permeator. Pol. J. Pharmacol., 56, 367-371.
16. Kuhajda K., Kevresan S., Kandrac J, Fawcett J.P., Mikov M. (2006): Chemical and metabolic transformations of selected bile acids. Eur. J. Drug Metab. Pharmacokinet., 31, 179-235.
17. Kuhalda K., Kevresan S., Mikov M., Sabo A., Miljkovic D. (2000): Influence of 3α,7α-dihydroxy-12-oxo-5β cholanate on blood glucose levels in rats. Arch. Toxicol. Kinet. Xenobiot. Metab., 8, 304-308.
18. Mikov M., Fawcett J. P., Kuhajda K., Kevresan S. (2006): Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur. J. Drug Metabol. Pharmacokinet., 31, 237-251.
19. Khavinson V.K. (2005): Effect of tetrapeptide on insulin biosynthesis in rats with alloxan-induced diabetes. Bull. Exp. Biol. Med., 140, 452-454.
20. Moursagaleeva G.N.; Khafizianova R.K., Kiyasov A.P. (1988): The elevating blood glucose levels as result of increasing of A-cell population in alloxan-induced diabetes in rats. Pathophysiology, 5 (Suppl. 1), 177.
21. Federiuk I.F., Casey H.M., Quinn M.J., Wood M.D., Ward W. K. (2004): Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment. Comp. Med., 54, 252-257.
22. Slonim A.E., Surber M.L., Page D.L., Sharp R.A., Burr I.M. (1983): Modification of chemically induced diabetes in rats by vitamin E. Supplementation minimizes and depletion enhances development of diabetes. J. Clin. Invest., 71, 1282-1288.
23. Miljkovic D, Kuhajda K., Hranisavljevic J. (1996): Selective C-12 oxidation of cholic acid. J. Chem. Res. 1996; Suppl: 106-107
24. Bachmann K., Pardoe D., White D.: Scaling basic toxicokinetic parameters from rat to man. Environ. Health Perspect., 104, 400-407.
25. Alam M.J., Rahman M.A. (1971): Changes in the saccharoid fraction in rats with alloxan-induced diabetes or injected with epinephrine. Clin. Chem., 17, 915-920.
26. Khavinson, V.K. (2005): Effect of tetrapeptide on insulin biosynthesis in rats with alloxan-induced diabetes. Bull. Exp. Biol. Med., 140, 452-454.
27. Park J.Y., Kim K.A., Park P.W., Park C.W., Shin J.G. (2003): Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin. Pharmacol. Ther., 74, 334-340.
28. Rouini M.R., Mohajer A., Tahami M.H. (2003): A simple and sensitive HPLC method for determination of gliclazide in human serum. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 785, 383-386.
29. Hsieh D. (ed) (1994). Drug Permeation Enhancement Theory and Applications. Marcel Dekker Inc. New York.
30. Alberts B., Bary D., Lewis J., Raff M., Roberts K., Watson J., eds (1983): Molecular Biology of the Cell. Garland, N.Y.
31. Gribble F.M., Ashcroft F.M. (2000): Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism, 49, 3-6.
32. Eloranta J.J., Kullak-Ublick G.A. (2005): Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys., 433, 397-412.
33. Zollner G., Fickert P., Silbert D., Fuchsbichler A., Stumptner C., Zatloukal K., Denk H., Trauner M. (2002): Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol., 282, G184-G191.
34. Iida M., Ikeda M., Kishimoto M., Tsujino T., Kaneto H., Matsuhisa M, et al. (2002): Evaluation of gut motility in type II diabetes by the radiopaque marker methodl. J. Gastroenerol. Hepatol., 15, 381-385.
35. Mikov M., Boni N.S., Al-Salami H., Kuhajda K, Kevresan S., Fawcett J. P. (2007): Bioavailability and hypoglycemic effect of the semisynthetic bile acid salt, sodium 3α,7α-dihydroxy-12-oxo-5β-cholanate (MKH), in healthy and diabetic rats. Eur. J. Drug Metabol. Pharmacokinet., 32, 7-12.